

Hideki Suganami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1978627/publications.pdf>

Version: 2024-02-01

23
papers

1,132
citations

706676

14
h-index

721071

23
g-index

24
all docs

24
docs citations

24
times ranked

1144
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of K-877 (Pemafibrate), a Selective PPAR α Modulator, in European Patients on Statin Therapy. <i>Diabetes Care</i> , 2022, 45, 898-908.	4.3	17
2	Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. <i>Cardiovascular Diabetology</i> , 2021, 20, 96.	2.7	16
3	Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1660-1665.	2.2	5
4	Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose cotransporter-2 inhibitor tofogliflozin, in relation to weight loss. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 222-230.	2.2	3
5	Association of increased hepatic insulin clearance and change in serum triglycerides or beta-hydroxybutyrate concentration via the sodium/glucose cotransporter 2 inhibitor tofogliflozin. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 947-956.	2.2	8
6	Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3647-3660.	1.8	18
7	Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARM α): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5537.	1.8	27
8	Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1737-1744.	2.2	35
9	Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1715-1724.	2.2	6
10	Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARM α), in Dyslipidemic Patients with Renal Impairment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 706.	1.8	53
11	Effects of a novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1323-1332.	1.1	32
12	Effects of Pemafibrate, a Novel Selective PPAR α Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. <i>Diabetes Care</i> , 2018, 41, 538-546.	4.3	122
13	Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00015.	1.0	10
14	Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 521-538.	0.9	97
15	Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 173-184.	0.6	127
16	This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin" unsubstantiated". <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2041-2042.	2.2	0
17	Efficacy of Pemafibrate on Atherogenic Dyslipidemia: Results of a Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Compared with Placebo. <i>Atherosclerosis Supplements</i> , 2018, 32, 25-26.	1.2	1
18	Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1267-1279.e4.	0.6	35

#	ARTICLE	IF	CITATIONS
19	Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1061-1065.	2.2	20
20	Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARM α), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. <i>Atherosclerosis</i> , 2017, 261, 144-152.	0.4	101
21	Effects of K-877, a novel selective PPAR α modulator (SPPARM α), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. <i>Atherosclerosis</i> , 2016, 249, 36-43.	0.4	146
22	Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 749-766.	0.9	77
23	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. <i>Cardiovascular Diabetology</i> , 2014, 13, 65.	2.7	168